A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: BGB-A445
DRUG: LBL-007
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: pemetrexed
DRUG: Paclitaxel
DRUG: Nab paclitaxel
DRUG: BGB-15025

Sponsor

BeiGene